ICH S1 Carcinogenicity Studies Guidelines

E1538045 UNEXPLORED

The ICH S1 Carcinogenicity Studies Guidelines are international harmonized standards that outline when and how long-term animal carcinogenicity studies should be conducted to assess the cancer-causing potential of new pharmaceuticals.

Try in SPARQL Jump to: Surface forms Disambiguation Referenced by

All labels observed (1)

Label	Occurrences
ICH S1 Carcinogenicity Studies Guidelines canonical	1

How this entity was disambiguated

This entity first appeared as the object of triple T22458038 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: ICH S1 Carcinogenicity Studies Guidelines
Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S1 Carcinogenicity Studies Guidelines]

A. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
The IARC Monographs on the Identification of Carcinogenic Hazards to Humans are authoritative scientific evaluations that classify agents, mixtures, and exposures according to their potential to cause cancer in humans.
B. Report on Carcinogens
The Report on Carcinogens is an authoritative, periodically updated U.S. government publication that identifies and profiles substances known or reasonably anticipated to cause cancer in humans.
C. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
E. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: ICH S1 Carcinogenicity Studies Guidelines
Target entity description: The ICH S1 Carcinogenicity Studies Guidelines are international harmonized standards that outline when and how long-term animal carcinogenicity studies should be conducted to assess the cancer-causing potential of new pharmaceuticals.

A. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
The IARC Monographs on the Identification of Carcinogenic Hazards to Humans are authoritative scientific evaluations that classify agents, mixtures, and exposures according to their potential to cause cancer in humans.
B. Report on Carcinogens
The Report on Carcinogens is an authoritative, periodically updated U.S. government publication that identifies and profiles substances known or reasonably anticipated to cause cancer in humans.
C. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
E. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
F. None of above. chosen

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals → relatedTo → ICH S1 Carcinogenicity Studies Guidelines ⓘ

All labels observed (1)

How this entity was disambiguated Show

Referenced by (1)

How this entity was disambiguated